GlassScriptPhysician profile
Kayla A Arantowicz
NPI 1669186581
$3,108.77
in general payments reported to CMS, 2019-2025
23 companies · $1,778 in 2025
The $1,778 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,331 · 2025: $1,778.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,886 · Travel and Lodging: $1,222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,886.44 |
| Travel and Lodging | $1,222.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,595.42 | 2024-2025 | Proclaim, Eterna |
| Teva Pharmaceuticals USA, INC. | $158.92 | 2025 | Austedo Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.38 | 2025 | Jardiance |
| Novo Nordisk INC | $139.81 | 2025 | Rybelsus, Ozempic, Saxenda |
| Hologic Sales and Service, LLC | $123.99 | 2025 | Aptima |
| Ucb, INC. | $111.30 | 2024 | Bimzelx |
| Astrazeneca Pharmaceuticals LP | $110.02 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.25 | 2025 | Xifaxan |
| Genzyme Corporation | $91.98 | 2024 | |
| Intuitive Surgical, INC. | $74.57 | 2025 | |
| Glaxosmithkline, LLC. | $56.11 | 2025 | Shingrix, Arexvy |
| Intra-Sana Laboratories | $50.00 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Viiv Healthcare Company | $45.85 | 2025 | Dovato, Apretude |
| Exact Sciences Corporation | $45.29 | 2024-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $37.72 | 2025 | Zepbound, Mounjaro |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $36.22 | 2025 | |
| Nalu Medical, INC. | $36.15 | 2024 | Nalu Neurostimulation System |
| Gilead Sciences, INC. | $28.89 | 2025 | |
| Sanofi-Aventis U.S. LLC | $26.01 | 2024 | |
| Janssen Pharmaceuticals, INC | $24.63 | 2025 | Spravato |
| Shield Therapeutics INC | $24.47 | 2025 | |
| Phadia US INC. | $23.10 | 2025 | Immunocap |
| Amgen INC. | $21.69 | 2024 | Prolia, Evenity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayla Arantowicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.